ABP-450

AEON Biopharma has appointed industry veteran Rob Bancroft as Chief Executive Officer to lead the company's development of ABP-450 for therapeutic applications.

Xenon Pharmaceuticals is progressing its Phase 3 epilepsy program with azetukalner, anticipating topline data from the X-TOLE2 study in the second half of 2025.

The FDA has accepted for review Satsuma Pharmaceuticals and SNBL's resubmitted NDA for STS101, a dihydroergotamine nasal powder, for acute migraine treatment.

The cervical dystonia therapeutics market is poised for growth, driven by advancements in R&D and the emergence of novel treatment options.

AEON Biopharma is aligned with the FDA on the 351(k) regulatory pathway for ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA).